See the Yahoo! wire story, here. Note that, in the alpha-prefix-descriptor for the drug candidate, below -- the "SCH" stands for legacy Schering-Plough. Candidates bearing the "MK" descriptors are legacy Merck. Just FYI [A slide from Old Schering's R&D Day 2008, at right -- click to enlarge]:
. . . .Merck announced today the completion of patient enrollment in the TRA 2˚P-TIMI 50 clinical trial, a Phase III, randomized, double-blind, placebo-controlled, multinational study of SCH 530348, the company’s investigational antiplatelet protease activated receptor-1 (PAR-1) inhibitor. The study, conducted by the Thrombolysis in Myocardial Infarction (TIMI) Study Group, reached its target of more than 26,000 patients. . . .
Now we wait -- perhaps as long as two years -- for results.
No comments:
Post a Comment